|
|
Volumn 10, Issue 11, 2011, Pages 798-800
|
|
Buy buy bispecific antibodies
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
BEVACIZUMAB;
BISPECIFIC ANTIBODY;
BLINATUMOMAB;
CATUMAXOMAB;
CD16 ANTIGEN;
CD3 ANTIGEN;
FBTA 05;
INFLIXIMAB;
MM 111;
MONOCLONAL ANTIBODY;
MT 110;
MT 111;
PERTUZUMAB;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ACUTE LYMPHOBLASTIC LEUKEMIA;
ANTIBODY ENGINEERING;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
ASCITES TUMOR;
B CELL LYMPHOMA;
BREAST CANCER;
CYTOTOXIC T LYMPHOCYTE;
DRUG HALF LIFE;
DRUG RESEARCH;
DRUG TARGETING;
HUMAN;
NATURAL KILLER CELL;
PRIORITY JOURNAL;
ANIMALS;
ANTIBODIES, BISPECIFIC;
CLINICAL TRIALS AS TOPIC;
DRUG DISCOVERY;
DRUG INDUSTRY;
HUMANS;
|
|
EID: 80155150449
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3581 Document Type: Article |
|
Times cited : (39)
|
|
References (0)
|
